Biohaven price target raised to $36 from $29 at Piper Sandler

Piper Sandler analyst Christopher Raymond raised the firm’s price target on Biohaven to $36 from $29 and keeps an Overweight rating on the shares following quarterly results. Progress continues across the preclinical and clinical pipelines with catalyst timing generally on track, the firm says. Piper continues to only ascribe value to BHV-7000, which the firm believes represents a potential billion-dollar opportunity in the focal epilepsy market.